Oncology Patients
15
2
2
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
1 terminated out of 15 trials
90.9%
+4.4% vs benchmark
7%
1 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (15)
Oncology Legal Navigation Study
Utilization of Virtual Reality to Increase Comfort and Reduce Procedural Distress During Port Insertion Into the Body
Effect of the Benson Relaxation Technique on Clinical Outcomes of Oncology Patients Admitted to Intensive Care Units
FOCUS ON US: Adapting the FOCUS Program for Sexual and Gender Minority (SGM) Cancer Patients and Caregivers
The Effect of Reiki on Hopelessness Level
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
A Study of AMG 820 in Subjects With Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
AMG 319 Lymphoid Malignancy FIH
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors